Literature DB >> 19584202

The syndrome of combined pulmonary fibrosis and emphysema.

Vincent Cottin1, Jean-François Cordier2.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19584202     DOI： 10.1378/chest.09-0538

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  32 in total

1.  Smoking-related idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Charlene Fell; Marie-Christine Aubry; Kevin Brown; Thomas Colby; Ulrich Costabel; Teri J Franks; Barry H Gross; David M Hansell; Ella Kazerooni; Dong Soon Kim; Talmadge E King; Masanori Kitachi; David Lynch; Jeff Myers; Sonoko Nagai; Andrew G Nicholson; Venerino Poletti; Ganesh Raghu; Moises Selman; Galen Toews; William Travis; Athol U Wells; Robert Vassallo; Fernando J Martinez
Journal:  Eur Respir J       Date:  2014-07-25       Impact factor: 16.671

2.  Prevalence and progression of combined pulmonary fibrosis and emphysema in asymptomatic smokers: A case-control study.

Authors:  Kum Ju Chae; Gong Yong Jin; Young Min Han; Yong Seek Kim; Su Bin Chon; Young Sun Lee; Keun Sang Kwon; Hye Mi Choi; David Lynch
Journal:  Eur Radiol       Date:  2015-02-14       Impact factor: 5.315

3.  Clinical and Genetic Associations of Objectively Identified Interstitial Changes in Smokers.

Authors:  Samuel Y Ash; Rola Harmouche; Rachel K Putman; James C Ross; Alejandro A Diaz; Gary M Hunninghake; Jorge Onieva Onieva; Fernando J Martinez; Augustine M Choi; David A Lynch; Hiroto Hatabu; Ivan O Rosas; Raul San Jose Estepar; George R Washko
Journal:  Chest       Date:  2017-05-12       Impact factor: 9.410

Review 4.  Combined pulmonary fibrosis and emphysema syndrome: a review.

Authors:  Matthew D Jankowich; Sharon I S Rounds
Journal:  Chest       Date:  2012-01       Impact factor: 9.410

5.  The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study.

Authors:  Takahiro Sato; Ichizo Tsujino; Ayako Sugimoto; Toshitaka Nakaya; Taku Watanabe; Hiroshi Ohira; Masaru Suzuki; Satoshi Konno; Noriko Oyama-Manabe; Masaharu Nishimura
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

6.  The prognostic impact of combined pulmonary fibrosis and emphysema in patients with clinical stage IA non-small cell lung cancer.

Authors:  Tomoyoshi Takenaka; Kiyomi Furuya; Koji Yamazaki; Naoko Miura; Kana Tsutsui; Sadanori Takeo
Journal:  Surg Today       Date:  2017-08-18       Impact factor: 2.549

7.  Prediction of survival by texture-based automated quantitative assessment of regional disease patterns on CT in idiopathic pulmonary fibrosis.

Authors:  Sang Min Lee; Joon Beom Seo; Sang Young Oh; Tae Hoon Kim; Jin Woo Song; Sang Min Lee; Namkug Kim
Journal:  Eur Radiol       Date:  2017-09-19       Impact factor: 5.315

8.  Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5).

Authors:  Dianne M Walters; Kevin M White; Ushma Patel; Martin J Davis; Roberta M Veluci-Marlow; Solomon Raju Bhupanapadu Sunkesula; James C Bonner; Jessica R Martin; Wes Gladwell; Steven R Kleeberger
Journal:  FASEB J       Date:  2013-11-27       Impact factor: 5.191

9.  Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

Authors:  David M Habiel; Milena S Espindola; Ana L Coelho; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2018-02-17       Impact factor: 4.307

10.  Effects of ambrisentan in a patient affected by combined pulmonary fibrosis and emphysema and by severe pulmonary hypertension: clinical, functional, and biomolecular findings.

Authors:  Fernando Roccia; Benedetta Campolo; Luca Gallelli; Carmen Spaccarotella; Annalisa Mongiardo; Daniela Falcone; Rocco Savino; Girolamo Pelaia; Ciro Indolfi; Rosario Maselli
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.